Company Shares of Seattle Genetics (NASDAQ:SGEN) Rally 0.34%

On a relative basis, the stock has outperformed the S&P 500 by 1.02% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.34% in the last 1 week, and is up 2.65% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have dropped -12.68% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $52.33 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $40.14 and the 200 Day Moving Average price is recorded at $36.48.

The stock has recorded a 20-day Moving Average of 5.16% and the 50-Day Moving Average is 7.99%.


Seattle Genetics (NASDAQ:SGEN): stock turned positive on Friday. Though the stock opened at $40.85, the bulls momentum made the stock top out at $42.11 level for the day. The stock recorded a low of $40.27 and closed the trading day at $41.45, in the green by 1.25%. The total traded volume for the day was 758,204. The stock had closed at $40.94 in the previous days trading.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (President and CEO) of Seattle Genetics Inc /Wa, Siegall Clay B had sold 7,618 shares worth of $308,072 in a transaction dated July 6, 2016. In this transaction, 7,618 shares were sold at $40.44 per share.

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Companys marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Companys pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics sugar-engineered antibody (SEA) technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.